PLC
CLYM

Peapod Lane Capital’s Climb Bio CLYM Stock Holding History

Peapod Lane Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$740K Sell
108,878
-457,114
-81% -$2.64M 0.61% 55
2025
Q4 		$2.26M Buy
565,992
+4,126
+0.7% +$9.91K 1.93% 20
2025
Q3 		$1.13M Buy
561,866
+6,199
+1% +$11.5K 1.01% 45
2025
Q2 		$689K Buy
555,667
+1,851
+0.3% +$2.3K 0.69% 48
2025
Q1 		$676K Buy
+553,816
New +$898K 0.76% 46

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Peapod Lane Capital's CLYM Position: Q1 2026 in Review

Peapod Lane Capital reduced its Climb Bio (CLYM) stake by 81% in Q1 2026, selling an estimated $2.64M and leaving 108,878 shares worth $740K. The position accounts for 0.61% of the portfolio, ranked #55.

Peapod Lane Capital first reported a position in CLYM in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.26M in Q4 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Peapod Lane Capital held 108,878 shares of Climb Bio worth $740K as of Q1 2026.
  • Peapod Lane Capital sold 457,114 Climb Bio shares in Q1 2026, an estimated $2.64M.
  • Climb Bio made up 0.61% of Peapod Lane Capital's portfolio in Q1 2026, its #55 holding.
  • Peapod Lane Capital first reported a position in Climb Bio in Q1 2025 and has held it in 5 quarters since.
  • Peapod Lane Capital's Climb Bio position peaked at $2.26M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Peapod Lane Capital's 13F filing for Q1 2026, filed 4 May 2026.